Ignite Creation Date:
2024-05-06 @ 8:26 AM
Last Modification Date:
2024-10-26 @ 12:00 PM
Study NCT ID:
NCT02732119
Status:
COMPLETED
Last Update Posted:
2021-05-05
First Post:
2016-04-04
Brief Title:
Study of Ribociclib With Everolimus Exemestane in HR HER2- Locally AdvancedMetastatic Breast Cancer Post Progression on CDK 46 Inhibitor
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-06-14
Start Date Type:
ACTUAL
Primary Completion Date:
2020-02-25
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-02-25
Completion Date Type:
ACTUAL
First Submit Date:
2016-04-04
First Submit QC Date:
April 4 2016
Study First Post Date:
2016-04-08
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2021-05-05
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-04-10
Last Update Post Date:
2021-05-05
Last Update Post Date Type:
ACTUAL